Greenwich LifeSciences Inc
Company Profile
Business description
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Contact
3992 Bluebonnet Drive
Building 14
StaffordTX77477
USAT: +1 832 819-3232
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,828.70 | 2.30 | 0.03% |
| CAC 40 | 7,715.60 | 7.87 | -0.10% |
| DAX 40 | 24,084.86 | 11.19 | 0.05% |
| Dow JONES (US) | 44,406.36 | 422.17 | -0.94% |
| FTSE 100 | 8,811.61 | 5.08 | 0.06% |
| HKSE | 24,134.74 | 246.91 | 1.03% |
| NASDAQ | 20,412.52 | 188.59 | -0.92% |
| Nikkei 225 | 39,688.81 | 101.13 | 0.26% |
| NZX 50 Index | 12,859.02 | 94.07 | 0.74% |
| S&P 500 | 6,229.98 | 49.37 | -0.79% |
| S&P/ASX 200 | 8,590.70 | 1.40 | 0.02% |
| SSE Composite Index | 3,497.48 | 24.35 | 0.70% |